Biotechnology

The French biopharma giant posts strong 2025 results and forecasts over 13% growth, fueled by a booming pipeline and unexpected market advantages.

A potential first therapy for Charcot-Marie-Tooth disease heads to a major conference, showing promising functional gains despite missing its primary goal.

New data reveals Mesoblast's cell therapy Ryoncil dramatically boosts survival in GvHD patients when used early, paving the way for a major adult trial.

As Caroline Dorsa retires, Biogen elects Dr. Maria Freire as its new chair, a strategic move placing deep scientific expertise at the helm for a critical period.

Life sciences consulting firm Trinity lands #7 in Vault's prestigious rankings, signaling a major shift toward technology-enabled commercialization.

A massive $313M federal funding win brings hope to the ALS community, pushing total investment past $1.6B. But how close are we to a real breakthrough?

A non-invasive device for spinal cord injury gains major international praise, signaling a shift in neurorehabilitation and a path to market.

Australian biotech Amplia Therapeutics is bringing its promising pancreatic cancer trial to the US, a key step in developing a drug that targets the disease's defenses.

After a decade-long battle with Stage 4 cancer, one patient's cure spotlights a revolutionary immunotherapy and its potential to change cancer treatment.

UCLA's Dr. Donald Kohn joins the Jeffrey Modell Foundation to discuss revolutionary gene therapies offering new hope for Primary Immunodeficiency patients.

At a key summit, Candel Therapeutics will showcase how its oncolytic virus, CAN-3110, uses biomarkers to fight one of the deadliest brain cancers.

A new collaboration with Datavant will securely connect real-world health data, aiming to speed up research and deliver life-saving therapies faster.

With key leadership promotions, AscellaHealth aims to streamline the complex path from drug discovery to patient delivery for life sciences companies worldwide.

Zelluna partners with Medpace for a first-in-human trial of its ZIMA-101 TCR-NK therapy, a new 'off-the-shelf' approach for hard-to-treat solid tumors.

South Korea's Hugel shatters sales records with a 105% surge in the Americas, signaling a major power shift in the global medical aesthetics market.

With a 135% revenue surge and a key FDA submission for its kidney transplant drug, Hansa Biopharma is poised for a pivotal year of expansion.

Discover how a brand born from cancer research is reshaping skincare with its launch at Ulta Beauty, making advanced biotech formulas accessible to everyone.

ARS Pharma's neffy challenges the EpiPen with new data on efficacy, cost-effectiveness, and patient preference, promising a less intimidating allergy emergency.

Celularity Inc. has secured a $12.2M cash injection by selling tax losses, a move set to accelerate its cutting-edge longevity and regenerative medicine pipeline.

Kincell Bio and RegCell partner to bring a groundbreaking, non-gene-edited Treg cell therapy for autoimmune diseases from the lab to clinical trials.